Initiator Pharma Management

Management criteria checks 2/4

Initiator Pharma's CEO is Claus Olesen, appointed in May 2016, has a tenure of 8.25 years. directly owns 4.3% of the company’s shares, worth SEK20.02M. The average tenure of the management team and the board of directors is 8.4 years and 5.8 years respectively.

Key information

Claus Olesen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	8.3yrs
CEO ownership	4.3%
Management average tenure	8.4yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

CEO

Claus Olesen (50 yo)

8.3yrs

Tenure

Dr. Claus Elsborg Olesen is Chief Executive Officer at Stipe Therapeutics. He serves Chief Executive Officer at Initiator Pharma A/S since May 02, 2016 and serves as its Director since September 19, 2016 a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Claus Olesen	Co-Founder	8.3yrs	no data	4.3% DKK 20.0m
Dan Peters	Co-Founder & CTO	8.6yrs	no data	no data
Ulf Simonsen	Co-Founder	no data	no data	1.23% DKK 5.7m
Mikael Thomsen	Co-Founder & Chief Development Officer	no data	no data	1.42% DKK 6.6m
Torgeir Vaage	Chief Financial Officer	8.6yrs	no data	no data
Allan Wehnert	Senior Vice President of Clinical and R&D Strategy & Portfolio Management	3.7yrs	no data	no data
Susanne Thomsen	Head of Clin Ops	no data	no data	no data
Rene Egebro	Head of CMC	no data	no data	no data

8.4yrs

Average Tenure

60yo

Average Age

Experienced Management: INIT's management team is seasoned and experienced (8.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Claus Olesen	Co-Founder	7.9yrs	no data	4.3% DKK 20.0m
Gunnar Magnus Severus Persson	Chairman of the Board of Directors	7.9yrs	no data	0.50% DKK 2.4m
Henrik Moltke	Director	7.9yrs	no data	0.26% DKK 1.2m
Irwin Goldstein	Member of Scientific & Clinical Advisory Board	3.7yrs	no data	no data
Gunilla Ekstrom	Independent Director	1.8yrs	no data	0.036% DKK 167.2k
Annette Colin	Director	3.6yrs	no data	0.75% DKK 3.5m
Peter Holm	Director	7.9yrs	no data	no data
Sue Goldstein	Member of Scientific & Clinical Advisory Board	3.7yrs	no data	no data

5.8yrs

Average Tenure

61.5yo

Average Age

Experienced Board: INIT's board of directors are considered experienced (5.8 years average tenure).

Initiator Pharma Management

Management criteria checks 2/4

Key information

Recent management updates

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

No independent directors

No independent directors

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Announces Management Changes

Recent updates

Now 20% undervalued

New major risk - Financial position

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

New minor risk - Shareholder dilution

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction

New minor risk - Financial position

Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial

Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine (IP2015)

Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Forecast breakeven date pushed back to 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations

No independent directors

Initiator Pharma A/S Provides an Update on Its Clinical Programs

Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study

Initiator Pharma A/S has completed a Follow-on Equity Offering in the amount of SEK 2.499998 million.

Initiator Pharma A/S Reports Positive Efficacy Data Outcome of the Iptn2021 Program Phase I Study to Assess Pain-Reducing Effects

No independent directors

Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB

Initiator Pharma A/S Signs Option Agreement for Late-Stage Drug Candidate

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Initiates Dosing in the IPTN2021 Program Phase I Study to Assess Pain Reducing Effects

Initiator Pharma A/S Announces an Update on its Clinical Programs

Initiator Pharma A/S Receives CTA Approval for Iptn2021 Program Phase I Study to Assess Pain Reducing Effects

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Initiator Pharma Includes the First Patient in Phase 2B Study with Iped2015 in Erectile Dysfunction Patients

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Initiator Pharma Receives Approval for Phase 2a Study with IP2018

Forecast to breakeven in 2023

Initiator Pharma A/S Files its Clinical Trial Application for its Planned Phase II Study in Erectile Dysfunction Patients with IPED2015

New 90-day high: kr5.58

New 90-day low: kr4.18

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Initiator Pharma A/S Announces Management Changes

Initiator Pharma A/S announces First patient dosed in Phase 2a trial with IP2018

Initiator Pharma A/S announced that it expects to receive SEK 23 million in funding from MAC Clinical Research Ltd

Initiator Pharma Secures Funding for IPED2015 clinical Phase 2b study

New 90-day low: kr4.69

New 90-day low: kr4.99

Initiator Pharma A/S has completed a Composite Units Offering.

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age